GlassScriptPhysician profile
Daniel A Fells
NPI 1265594840
$5,286.56
in general payments reported to CMS, 2019-2025
35 companies · $18.48 in 2025
The $18.48 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,483 · 2022: $1,134 · 2023: $1,023 · 2024: $628 · 2025: $18.48.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,661 · Education: $9.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,660.67 |
| Education | $9.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $830.38 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $650.21 | 2021-2024 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $526.52 | 2021-2024 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $495.56 | 2021-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Insulet Corporation | $397.16 | 2021-2023 | Omnipod |
| Mylan Specialty L.P. | $319.08 | 2021-2024 | Yupelri |
| Lilly USA, LLC | $318.64 | 2021-2024 | Mounjaro, Jardiance, Trulicity |
| Pfizer INC. | $203.34 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $165.03 | 2021-2024 | Spiriva Respimat, Stiolto Respimat, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $159.95 | 2021-2024 | |
| Amgen INC. | $148.61 | 2021-2024 | Otezla, Repatha |
| Mannkind Corporation | $132.35 | 2021-2023 | Afrezza |
| E.R. Squibb & Sons, L.L.C. | $105.42 | 2021-2024 | Eliquis |
| Biohaven Pharmaceutical Holding Company LTD. | $81.81 | 2022 | |
| Scilex Pharmaceuticals INC. | $76.61 | 2021-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $69.10 | 2021 | |
| Phathom Pharmaceuticals, INC. | $63.86 | 2023-2024 | Voquezna |
| Esperion Therapeutics, INC. | $43.63 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $42.08 | 2022 | |
| Janssen Pharmaceuticals, INC | $42.02 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $40.94 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.28 | 2024 | Relistor, Xifaxan |
| Dexcom, INC. | $39.00 | 2021-2023 | Dexcom G6 Transmitter |
| Kowa Pharmaceuticals America, INC. | $35.54 | 2023 | Seglentis |
| Exact Sciences Corporation | $33.07 | 2023 | Cologuard Collection Kit |
| Lundbeck LLC | $31.68 | 2024 | Rexulti |
| Grifols USA, LLC | $31.62 | 2021 | |
| Irhythm Technologies, INC. | $30.95 | 2022 | |
| Alnylam Pharmaceuticals INC. | $23.44 | 2023 | Onpattro |
| Ironwood Pharmaceuticals, INC | $22.30 | 2021 | |
| Impel Pharmaceuticals INC. | $22.19 | 2022 | |
| Indivior INC. | $18.48 | 2025 | Sublocade |
| Abbott Laboratories | $17.37 | 2022 | |
| Almatica Pharma LLC | $15.70 | 2021 | |
| Gilead Sciences, INC. | $12.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Fells listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.